Kornimate/medical-research-clean huggingface dataset:
prolonged anticoagulation therapy on the prognosis of patients with left ventricular thrombosis

Conditions: Embolism and Thrombosis; Anticoagulation

Summary: a single-center, open-label, exploratory randomized controlled study is proposed with the following objectives: whether prolonging the duration of anticoagulation to 12 months, compared with 6 months of routine anticoagulation, helps to reduce major adverse cardiovascular and cerebrovascular events in patients with left ventricular thrombosis and to reduce recurrence of thrombosis, as well as to assess their bleeding risk. patients with a definite diagnosis of left ventricular thrombus and age ≥18 years were included in cardiac ultrasound (including general ultrasound and sonography) and other examinations during hospitalization and outpatient visits. exclusion criteria were detailed in the study protocol. grouping: according to the duration of anticoagulation, they were divided into extended anticoagulation group (12 months) and conventional anticoagulation group (6 months). intervention: this study is planned to extend the administration of rivaroxaban (pulsatilla) 20 mg to 12 months in the experimental group. the conventional anticoagulation group will take the drug for 6 months study endpoints: the primary efficacy endpoint is a major cardiovascular-vascular adverse event at 1 year; the primary safety endpoint is bleeding of grade 3 or higher as defined by the barc classification at 1 year. patient follow-up program: subjects will require a total of 12 on-site follow-up visits (one per month) for safety evaluation, efficacy evaluation, medication adherence evaluation, and imaging follow-up at months 3, 6, and 12.


Eligibility criteria:
inclusion criteria: ①patients who have been clearly diagnosed with left ventricular thrombus by inpatient or outpatient cardiac ultrasound (including general ultrasound and acoustic imaging). ②age \>= 18 years old exclusion criteria: * patients do not agree to participate in the study or have poor compliance in the past * contraindication to anticoagulation or allergy to anticoagulants ③have received oral anticoagulation after diagnosis of left ventricular thrombus. * have undergone or are planning to undergo surgical procedures including left ventricular appendage thrombectomy, heart transplantation, ventricular wall tumor collapse, or valve replacement. * presence of other long-term indications for anticoagulation, such as mechanical valve implantation, atrial fibrillation, etc. * requirement for treatment with tegretol and inability to change to clopidogrel bisulfate ⑦presence of known malignant tumors, severe hepatic dysfunction (child-pugh classification b or less), severe renal dysfunction (creatinine clearance \<30ml/min), anemia (hb \<100g/l), coagulation disorders and other underlying diseases, or life expectancy \<3 years ⑧ female patients are pregnant or breastfeeding ⑨ patients with antiphospholipid syndrome
nebulized fentanyl for respiratory symptoms in patients with covid-19

Conditions: COVID-19 Pneumonia

Summary: patients with coronavirus disease (covid-19) experience distressing and challenging to manage respiratory symptoms. interventions such as oxygen (o2) therapy, oral opiates, and traditional nebulizers like ipratropium bromide and salbutamol, are variably effective, and therapeutic responses in individual patients are difficult to predict. the purpose of this study is to investigate the efficacy of nebulized fentanyl citrate on dyspnea, cough, and throat pain in patients with covid-19, as well as evaluate the safety with any potential adverse events. in covid-19, about 59% of patients will exhibit cough, 35% generalized body ache and sore throat and 31% will have dyspnea. nebulized lidocaine, magnesium, and opioids are alternative methods for the management of respiratory symptoms in various patients. fentanyl nebulization was found to be effective in decreasing dyspnea in chronic obstructive pulmonary disease (copd) patients by decreasing the rate of spontaneous respiratory rate, modulating cortical activity, and diminishing the brain stem chemoreceptor response to hypoxia and hypercarbia. the investigators hypothesize that nebulized fentanyl is superior to nebulized saline in suppressing cough, respiratory drive, improving breathlessness or dyspnea with the additional advantage of throat pain relief with minimal adverse effects in patients with covid-19.


Eligibility criteria:
inclusion criteria: * age: 18 - 65 years * confirmed diagnosis (covid-19) - positive pcr * tachypnoea (respiratory rate\> 30/min) * ability to provide informed consent and perform all study procedures exclusion criteria: * history of allergy or adverse reaction to fentanyl or other opioids * pregnancy * active neuromuscular or musculoskeletal disease. * active malignancy * morbid obesity (body mass index \>40) * use of opioids in the previous 4 weeks. * inability to provide informed consent and perform all study procedures.
rheumatic immune-related adverse events in patients treated with immune check point inhibitors

Conditions: Immune-related Adverse Event

Summary: rimra is a prospective, longitudinal, observational study including patients with de novo symptoms of rheumatic disease or a flare of established rheumatic disease after treatment with an immune check point inhibitor. the aim of the study is to describe the clinical presentation, disease course and outcome of rheumatic iraes in patients treated with immune check point inhibitors.


Eligibility criteria:
inclusion criteria: * de novo symptoms of rheumatic disease or a flare of established rheumatic disease after \>/= 1 dose of treatment with an immune check point inhibitor * adult patients (\> 18 years) * subject capable of understanding and signing an informed consent form exclusion criteria: • psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol difficult

Keywords: arthritis check point inhibitor irae
a revised tafenoquine dose to improve radical cure for vivax malaria

Conditions: Vivax Malaria

Summary: the goal of this clinical trial is to assess the efficacy and safety or a revised weight band tafenoquine dose in vivax malaria patients. the main question\[s\] it aims to answer are: * is a revised weight-based tq regimen (tqrevised: target dose 7.5mg/kg) non-inferior to high dose primaquine (7mg/kg over 7 days) * is a revised weight-based tq regimen (tqrevised: target dose 7.5mg/kg) superior to fixed dose tafenoquine (300mg) * is the tolerability and safety of tqrevised acceptable * is tqrevised acceptable and feasible participants will receive a tafenoquine target dose 7.5mg/kg in weight bands. researchers will compare this to patients receiving a fixed dose tafenoquine and high dose primaquine to see if safe and effective.


Eligibility criteria:
inclusion criteria: * p. vivax peripheral parasitaemia (mono-infection) * g6pd normal status (g6pd activity ≥70% of the adjusted male median as determined by the standard g6pd (sdbioline, rok)) * fever (temperature ≥37.5⁰c) or history of fever in the preceding 48 hours * written informed consent * living in the study area and willing to be followed for six months exclusion criteria: * danger signs or symptoms of severe malaria * anaemia (defined as hb \<8g/dl) * pregnant or lactating females * regular use of drugs with haemolytic potential * known hypersensitivity to any of the study drugs.
clinical characteristics of deceased with covid-19

Conditions: Covid19

Summary: this study aims to describe the clinical characteristics of patients who died from covid-19 in the largest hospital in bangladesh to understand the risk associated with covid-19 related mortality in this region. this is a retrospective study where a review of hospital records of patients will be done who died from covid-19 in dhaka medical college hospital from 3rd may to 31 august 2020. all available demographic, clinical, laboratory information, radiological feature, and patients' management will be retrieved from the record section to be analyzed and described.

in this retrospective observational study, every consecutive patient who died and tested positive for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in dhaka medical college hospital from 2nd may 2020 to 31 august 2020 were included. the paper files of patients were retrieved from the record section of the hospital as only a paper-based recording is maintained in the hospital. patients with suspected covid-19 were excluded from the study who tested negative for reverse transcriptase polymerase chain reaction (rt pcr for sars-cov-2). a preformed case record form (crf) was used to collect all available demographic, clinical information including presentation, investigation, and treatment from hospital paper file from the record section. the severity of disease for covid-19 was classified according to national guidelines on clinical management of covid-19 version 8.0, 5 november 2020. the mild disease was defined as an individual with covid-19 with prodromal symptoms without dyspnea and radiological abnormality. the moderate disease was defined as abnormal chest imaging with the saturation of oxygen ≥ 90% and severe disease was denied as saturation of oxygen less than 90%. all data were summarized, analyzed with spps 26. rt pcr for sars-cov-2 assay is done in the virology department of dhaka medical college to detect sars-cov-2 rna from samples taken from suspected patients. nasopharyngeal swabs and the oropharyngeal swab were taken from patients. biochemical, hematological investigations are done in the clinical pathology department of the hospital and paper reports are sent to respective patients' files. laboratory measurements were collected for analysis which is available in the file of deceased patients in the record section.

Eligibility criteria:
inclusion criteria: * all patients died from covid-19 confirmed with rt pcr for sars-cov-2 exclusion criteria: * suspected covid-19 patients negative for rt pcr for sars-cov-2 and * age less than 14 year

Keywords: covid19 clinical characteristics deceased
pet imaging of vaso-occlusive crisis (voc) in scd

Conditions: Sickle Cell Disease

Summary: the purpose of this study is to find objective biomarkers of vaso-occlusion (blood vessel blockage) in people with scd. using information from earlier studies and work being done, researchers have developed a strategy to image voc, using positron emission tomography (pet). the ability to see and measure voc in scd patients can help patient care, by showing when and how a voc is occurring or going to occur. studying this method will also help in future drug research, as it will allow researchers to deliver promising new medications that target hyper-adhesion and sickling in people with scd.

the purpose of this study is to find objective biomarkers of vaso-occlusion (blood vessel blockage) in people with sickle cell disease(scd). using information from earlier studies, and work being done at washington university, a strategy to image vaso-occulusive crisis (voc) has been developed, using positron emission tomography (pet) for anatomical localization only. 64cu-llp2a is the radio tracer used for the study. aim: to develop quantitative pet imaging of voc in patients with scd. the researchers hypothesize that the radio tracer 64cu-llp2a uptake increases proportionally to the intensity of pain in patients with voc, compared to baseline values. this increase in uptake will be assessed focally in areas of pain as well as globally to reflect heightened systemic inflammation. primary and secondary study endpoint: the overarching hypothesis of this study is that pet tracer uptake of intensity of 64cu-llp2a is a real time, quantitative measure of hyper adhesion in voc.

Eligibility criteria:
inclusion criteria: * have a confirmed diagnosis of scd (hbss, sc, s/β-thalassemia, sd, se, so) by hemoglobin electrophoresis/high performance liquid chromatography (hplc) * aged 18 and above * ability to understand and provide informed consent. * if receiving hydroxyurea or l-glutamine, crizanlizumab, voxelotor or erythropoietin stimulating agents, must have been receiving the drug for at least 12 weeks prior to screening and plan to continue taking the drug at the same dose and schedule during the study * experienced at least 2 vocs leading to healthcare visit within the 12 months prior to screening visit as determined by medical history. exclusion criteria: * active malignancy * current pregnancy or breast feeding * participating in a chronic transfusion program (pre-planned series of transfusions for prophylactic purposes) and/or planning on undergoing an exchange transfusion during the duration of the study; episodic transfusion in response to worsened anemia or voc is permitted * received active treatment on another investigational trial within 30 days (or 5 half-lives of that agent, whichever is greater) prior to screening visit or plans to participate in another investigational drug trial

Keywords: pet mri
a dose escalation study of l-dos47 in recurrent or metastatic non-squamous nsclc

Conditions: Non-Small Cell Lung Cancer

Summary: the primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of l-dos47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with stage iv (tnm m1a and m1b) recurrent or metastatic non-squamous non-small cell lung cancer.

it is planned that patients will receive 4 cycles of combination treatment with l-dos47 + pemetrexed/carboplatin. patients who have not progressed following the 4 cycles of combination treatment and who have not experienced unacceptable toxicity will have the opportunity to continue to receive l-dos47 treatment for as long as there is clinical benefit and it is well-tolerated, in the opinion of the investigator, until disease progression. patients who are unable to complete 4 cycles of l-dos47 + pemetrexed/carboplatin combination treatment due to pemetrexed/carboplatin toxicity will have the opportunity to continue receiving l-dos47 treatment following discontinuation of pemetrexed/carboplatin, for as long as there is clinical benefit and it is well-tolerated, in the opinion of the investigator, until disease progression.

Eligibility criteria:
main inclusion criteria: 1. male or female patient ≥ 18 years of age 2. histologically or cytologically confirmed non-squamous nsclc 3. egfr-mutation positive patients must have progressed on or had intolerance to an egfr small molecule tyrosine kinase inhibitor 4. patients whose tumors harbor an anaplastic lymphoma kinase (alk) translocation must have progressed on or had intolerance to an alk inhibitor; 5. no prior adjuvant chemotherapy within 1 year of the first treatment day if there is recurrent disease 6. at least 1 site of measurable disease per response evaluation criteria in solid tumors (recist) v1.1 7. eastern cooperative oncology group (ecog) performance status of 0 or 1 and minimum life expectancy of ≥ 3 months 8. adequate bone marrow, renal and liver function main exclusion criteria: 1. histologic evidence of predominantly squamous cell nsclc 2. brain metastasis and/or leptomeningeal disease (known or suspected) 3. peripheral neuropathy \> ctcae grade 1 4. possibility of a curative local treatment (surgery and/or radiotherapy) 5. previous chemotherapy except adjuvant treatment with progression of disease documented ≥ 12 months after end of adjuvant treatment 6. having received treatment in another clinical study within the 30 days prior to commencing study treatment or having side effects of a prior study drug that are not recovered to grade ≤ 1 or baseline, except for alopecia 7. concurrent chronic systemic immunotherapy, chemotherapy or hormone therapy

Keywords: non-small cell lung cancer neoplasms immunoconjugate tumor microenvironment alkalinization
a study in patients with non-small cell lung cancer to test if erlotinib plus su011248 is better than erlotinib alone

Conditions: Carcinoma, Non-Small Cell Lung

Summary: this study will test whether treatment with erlotinib plus su011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.


Eligibility criteria:
inclusion criteria: * patients with locally advanced/metastatic non-small cell lung cancer * prior treatment with no more than 2 chemotherapy regimens including a platinum-based regimen exclusion criteria: * prior treatment with any receptor tyrosine kinase inhibitors, vegf inhibitor (with the exception of bevacizumab) or other angiogenesis inhibitors * history of or known brain metastases

Keywords: non-small cell lung cancer sunitinib erlotinib phase 3
cerebrospinal fluid biomarkers in bariatric surgery

Conditions: Obesity

Summary: the goal of this project is to understand why bariatric surgery is such an effective treatment for obesity with a focus on brain mechanisms. cerebrospinal fluid (csf) neuropeptide, hormone and protein levels will be measured as a surrogate for changes in brain activity in participants before and after bariatric surgery as compared with participants before and after diet-induced weight loss. the investigators are studying neuropeptides and hormones that are know to be involved with the regulation of appetite and body weight to determine if some of the changes that are expected to occur after diet-induced weight loss do not occur after bariatric surgery. in addition, proteomic analysis will be used to uncover new protein biomarkers that are unique to surgical weight loss. the results of these studies will help explain why bariatric surgery is so effective in achieving long-term weight loss. understanding how the central nervous system responds to bariatric surgery could help the development of alternative nonsurgical therapies for obesity and its metabolic complications.

peripheral metabolic signals communicate levels of energy stores to the brain and elicit a host of neuronal responses that maintain energy balance; such regulatory mechanisms make it difficult to maintain diet-induced weight loss. the goal is to understand how these central regulatory mechanisms are circumvented following surgical alterations in the gut in subjects after roux-en-y gastric bypass (rygb) and vertical sleeve gastrectomy (sg) compared to carefully matched diet- induced weight loss controls who achieve weight loss on a low calorie liquid diet. surgery participants will be patients who have already chosen to have a bariatric surgery procedure with their doctor. diet participants will be provided with the low calorie liquid diet for approximately 3 months and will be monitored weekly throughout the study. surgery participants will be studied at 3 time-points: 1. before the intervention 2. after surgery at 10-15% weight loss 3. at 12 months after surgery low calorie diet participants will be studied at 2 time-points: 1. before intervention 2. at 10-15% weight loss (approximately 12 weeks on the diet) at each time-point subjects will have a lumbar puncture (spinal tap) for cerebrospinal fluid (csf) sampling and blood will be collected in the fasting state and in response to a liquid meal challenge. body weight, waist and hip circumference will be measured.

Eligibility criteria:
inclusion criteria: * 18-65 years old * bmi 35-55 exclusion criteria: * no clinically significant medical conditions * no use of tobacco * no alcohol or drug abuse * no recent weight change (+/-5%) within prior 6 months * no medications that may affect body weight or blood glucose * no diabetes medications, beta-blockers, opiates or glucocorticoids * no pregnancy, breastfeeding, or planning to become pregnant during the study (diet group only) * no lactose intolerance

Keywords: obesity bariatric surgery gastric bypass sleeve gastrectomy weight loss low calorie diet
d3-ghr polymorphism and turner syndrome

Conditions: Turner Syndrome; Short Stature

Summary: the protein polymorphism of the growth hormone receptor characterized by the genomic deletion of exon 3 has been linked to the magnitude of the first-year-growth response to growth hormone (gh) in girls with turner syndrome. objective: to study the long-term effect of gh therapy in turner syndrome in correlation to this ghr polymorphism in a mainly retrospective design (chart-review).


Eligibility criteria:
inclusion criteria: * turner syndrome defined by a structural aberration or lack of the x chromosome. * growth velocity less than 2 cm/year at the time of final analysis (= final height). exclusion criteria: * age \ 14 years at start of gh therapy, * gh peak serum levels \< 8 ng/ml in two independent tests, * thelarche at start or during the first year of treatment, * oxandrolone therapy for any time and a duration of gh therapy less than 2 years.

Keywords: growth hormone receptor polymorphism pharmacogenomics growth promoting therapy
impact of thoracic epidural versus serratus anterior plane block versus erector spinae plane block on incidence of ptps

Conditions: Post-thoracotomy Pain Syndrome; Erector Spinae Plane Block; Serratus Anterior Plane Block

Summary: the aim of this study is to evaluate the impact of ultrasound-guided erector spinae plane block compared to ultrasound-guided serratus anterior plane block on the emergence of post-thoracotomy pain syndrome in patients undergoing lobectomy for lung cancer.

lung cancer has the highest incidence of all malignancies worldwide and accounts for approximately 13% of all cancer cases. lung cancer is still the most common cause of cancer-related deaths, and lung resection surgeries could be the main therapeutic option. hence, the number of thoracotomy procedures is progressively increasing as is the incidence of post-thoracotomy pain. in addition to amputation and mastectomy, thoracotomy is considered the main etiology of severe and long-term acute and chronic post-surgical pain syndromes (cpsps). the prevalence of post-thoracotomy pain syndrome (ptps) is widely variable (30%-50%) and may range from 11% to 80%, according to other studies. the international association for the study of pain (iasp) has defined post-thoracotomy pain syndrome as "pain that recurs or persists along the thoracotomy scar at least 2 months after the procedure". in addition, post-thoracotomy pain syndrome is mostly described with neuropathic manifestations along the thoracotomy scar and in the mammary, inframammary, ipsilateral scapular and interscapular areas. the ultrasound-guided erector spinae plane (esp) block is a novel technique for thoracic analgesia that promises to be a relatively simple and safe alternative to more complex and invasive techniques of neural blockade.

Eligibility criteria:
inclusion criteria: * age (18-65) years * physical status american society of anesthesiologists classification ii, iii * patients undergoing lobectomy through lateral thoracotomy * body mass index (bmi): (20-40) kg/m2 exclusion criteria: * patient refusal. * age \ 65 years * body mass index (bmi) \ 40 kg/m2 * known sensitivity or contraindication to drugs used in the study * contraindication to regional anesthesia e.g. local infection at site of introduction, pre-existing peripheral neuropathies and coagulopathy. * pregnancy. * physical status american society of anesthesiologists classification iv * patients on chronic analgesic therapy (daily morphine ≥30 mg or equivalent dose of other opioids or tramadol or any medication for neuropathic pain) * patients with a history of drug abuse * patients with neuropsychiatric diseases; patients with a history of chronic pain syndromes that may enhance sensitivity to pain, for example, fibromyalgia * patients with a history of thoracic surgery through lateral thoracotomy; and patients with recurrent chest malignancies within 3 months. * all patients who developed severe intra- or post-operative bleeding or required postoperative mechanical ventilation were also excluded from the study. * thoracic spine disorders or deformity.